5 billion in the second quarter.

Kaiser Family Foundation. Kaiser Health News, an independent news service editorially, is a scheduled program of the Kaiser Family members Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.. $1,000-a-pill hepatitis C drug boosts Gilead’s fortunes Sales of the brand new hepatitis C drug Sovaldi reached $3.5 billion in the second quarter, placing it on the right track to become among the world's best-selling medicines and intensifying concerns about its costs.5 billion in the second quarter, a huge figure that puts it on the right track to become one of the world's best-selling medicines but could intensify worries about culture's capability to pay for it.Related StoriesHealthcare technology public event of the entire year opens entriesOJ Bio at Medica 2015 – Point of Care diagnostics' role in reducing antibiotics prescribingReducing hospital readmissions through Transitional Care: an interview with Rani KhetarpalCompression therapy is known as a standard of care for treating venous hypertension and venous ulcers, which certainly are a serious issue for many Americans, like the elderly and folks with vascular disease or poor circulation.